PathClear HC20+ claims the advantage of lot-to-lot consistency and controlled protein concentrations to support in vivo angiogenesis assays and tumorigenicity assays
Trevigen announces the immediate availability of PathClear basement membrane extract high protein concentration (HC20+) in the Cultrex product line.
The PathClear designation means that in addition to standard sterility, endotoxin and MAP testing, the BME is tested by PCR and is clear of a battery of 31 pathogens and viruses, including LDEV, making it ideal for in vivo applications.
Each lot is rigorously qualified in biological performance assays.
PathClear HC20+ was developed for use in in vivo applications where higher protein concentrations facilitate faster gelling times, increased gel strength, and successful establishment and growth of tumor cells in nude mice.
Trevigen develops, manufactures and markets an extensive line of Cultrex brand products for the promotion of cell growth, cellular differentiation and for the study of cancer cell behaviour.
